Gempharmatech Co. Ltd. A (688046) - Total Liabilities
Based on the latest financial reports, Gempharmatech Co. Ltd. A (688046) has total liabilities worth CN¥630.58 Million CNY (≈ $92.27 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 688046 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Gempharmatech Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Gempharmatech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See Gempharmatech Co. Ltd. A free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Gempharmatech Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Gempharmatech Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pebblebrook Hotel Trust
NYSE:PEB
|
USA | $2.77 Billion |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
USA | $314.75 Million |
|
Grand City Properties SA
F:GYC
|
Germany | €5.57 Billion |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €30.18 Million |
|
Metrics Master Income Trust
AU:MXT
|
Australia | AU$16.75 Million |
|
Pavilion Real Estate Inv Trust
KLSE:5212
|
Malaysia | RM4.34 Billion |
|
Robertet SA
PA:RBT
|
France | €399.53 Million |
|
Wangfujing
SHG:600859
|
China | CN¥19.44 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Gempharmatech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gempharmatech Co. Ltd. A market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gempharmatech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gempharmatech Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of Gempharmatech Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥437.92 Million ≈ $64.08 Million |
-3.31% |
| 2023-12-31 | CN¥452.93 Million ≈ $66.28 Million |
+64.10% |
| 2022-12-31 | CN¥276.00 Million ≈ $40.39 Million |
+2.69% |
| 2021-12-31 | CN¥268.78 Million ≈ $39.33 Million |
+18.95% |
| 2020-12-31 | CN¥225.95 Million ≈ $33.06 Million |
+53.02% |
| 2019-12-31 | CN¥147.66 Million ≈ $21.61 Million |
-- |
About Gempharmatech Co. Ltd. A
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides cust… Read more